AACR 2002 follow-up
This article was originally published in The Tan Sheet
Executive Summary
Finding that plasma homocysteine concentrations are not associated with increased breast cancer risk "seems to contradict the recently suggested role of homocysteine as a potential tumor marker," Katharina Schroecksnadel, Leopold Franzen University, Australia, et al. state in July 16 Journal of the National Cancer Institute. Comments respond to study results by Shumin Zhang, Harvard School of Public Health, et al. that found high concentrations of vitamin B12 and plasma folate were associated with a lower risk of breast cancer (1"The Tan Sheet" April 15, 2002, p. 15). Zhang and colleagues point out that the study was not meant to consider the role of homocysteine as a tumor marker, but "data would suggest that it does not appear early in the disease process"...
You may also be interested in...
AACR Annual Meeting In Brief
Shanghai Breast Cancer Study: Green tea consumption associated with 15% decreased breast cancer risk, Martha Shrubsole, Vanderbilt University and Shanghai Cancer Institute, et al., report at American Association of Cancer Research annual meeting in San Francisco, Calif. April 6-10. Risk further declined with increased years of green tea consumption, number of servings/day. Multivitamin intake led to 48% reduced risk, with 30%, 25%, 27% decreases in breast cancer risk associated with vitamin B, C, E consumption, respectively; no duration or dose-response correlations were detected. Ginseng use did not ameliorate breast cancer risk. Study involved in-person interviews with 1,459 cases and 1,556 controls...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.